{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:23:20Z","timestamp":1783419800915,"version":"3.54.6"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["metabolismjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.metabol.2021.154779","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T06:54:59Z","timestamp":1619160899000},"page":"154779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis"],"prefix":"10.1016","volume":"120","author":[{"given":"Shanshan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingya","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruizhi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhan","family":"Bie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuojun","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiange","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieli","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufang","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2021.154779_bb0005","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2021.154779_bb0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2021.154779_bb0015","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","article-title":"New trends on obesity and NAFLD in Asia","volume":"67","author":"Fan","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2021.154779_bb0020","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.metabol.2016.01.012","article-title":"Epidemiology and natural history of non-alcoholic fatty liver disease","volume":"65","author":"Fazel","year":"2016","journal-title":"Metabolism."},{"key":"10.1016\/j.metabol.2021.154779_bb0025","doi-asserted-by":"crossref","unstructured":"Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999\u20132014.e1. doi: https:\/\/doi.org\/10.1053\/j.gastro.2019.11.312.","DOI":"10.1053\/j.gastro.2019.11.312"},{"key":"10.1016\/j.metabol.2021.154779_bb0030","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14548","article-title":"Comparison of MAFLD and NAFLD diagnostic criteria in real world","volume":"40","author":"Lin","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.metabol.2021.154779_bb0035","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41569-018-0119-4","article-title":"Epidemiology of cardiovascular disease in China: current features and implications","volume":"16","author":"Zhao","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.metabol.2021.154779_bb0040","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1161\/CIRCULATIONAHA.120.046361","article-title":"et al; PROG-IMT and the Proof-ATHERO Study Groups. Carotid intima-media thickness progression as surrogate marker for cardiovascular risk: meta-analysis of 119 clinical trials involving 100 667 patients","volume":"142","author":"Willeit","year":"2020","journal-title":"Circulation."},{"key":"10.1016\/j.metabol.2021.154779_bb0045","doi-asserted-by":"crossref","unstructured":"Ohkuma T, Ninomiya T, Tomiyama H, Kario K, Hoshide S, Kita Y, Inoguchi T, Maeda Y, Kohara K, Tabara Y, Nakamura M, Ohkubo T, Watada H, Munakata M, Ohishi M, Ito N, Nakamura M, Shoji T, Vlachopoulos C, Yamashina A; Collaborative Group for J-BAVEL (Japan Brachial-Ankle Pulse Wave Velocity Individual Participant Data Meta-Analysis of Prospective Studies)*. Brachial-ankle pulse wave velocity and the risk prediction of cardiovascular disease: an individual participant data meta-analysis. Hypertension. 2017;69:1045\u20131052. doi: https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.09097.","DOI":"10.1161\/HYPERTENSIONAHA.117.09097"},{"key":"10.1016\/j.metabol.2021.154779_bb0050","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2215\/CJN.03190906","article-title":"Microalbuminuria and cardiovascular disease","volume":"2","author":"Weir","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.metabol.2021.154779_bb0055","doi-asserted-by":"crossref","unstructured":"Huang Y, Bi Y, Xu M, Ma Z, Xu Y, Wang T, Li M, Liu Y, Lu J, Chen Y, Huang F, Xu B, Zhang J, Wang W, Li X, Ning G. Nonalcoholic fatty liver disease is associated with atherosclerosis in middle-aged and elderly Chinese. Arterioscler Thromb Vasc Biol 2012;32:2321\u20132316. doi: https:\/\/doi.org\/10.1161\/ATVBAHA.112.252957.","DOI":"10.1161\/ATVBAHA.112.252957"},{"key":"10.1016\/j.metabol.2021.154779_bb0060","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jhep.2017.12.012","article-title":"Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: an observational cohort study","volume":"68","author":"Lee","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2021.154779_bb0065","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1445-5994.2009.01979.x","article-title":"Impact of non-alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes","volume":"40","author":"Hwang","year":"2010","journal-title":"Intern Med J"},{"key":"10.1016\/j.metabol.2021.154779_bb0070","doi-asserted-by":"crossref","unstructured":"Sinn DH, Cho SJ, Gu S, Seong D, Kang D, Kim H, Yi BK, Paik SW, Guallar E, Cho J, Gwak GY. Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis. Gastroenterology. 2016;151:481\u2013488.e1. doi: https:\/\/doi.org\/10.1053\/j.gastro.2016.06.001.","DOI":"10.1053\/j.gastro.2016.06.001"},{"key":"10.1016\/j.metabol.2021.154779_bb0075","doi-asserted-by":"crossref","first-page":"154433","DOI":"10.1016\/j.metabol.2020.154433","article-title":"MAFLD and risk of CKD","volume":"115","author":"Sun","year":"2021","journal-title":"Metabolism."},{"key":"10.1016\/j.metabol.2021.154779_bb0080","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1210\/jc.2011-3010","article-title":"Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese","volume":"97","author":"Li","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2021.154779_bb0085","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.2337\/diacare.21.12.2191","article-title":"Correct homeostasis model assessment (HOMA) evaluation uses the computer program","volume":"21","author":"Levy","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154779_bb0090","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.metabol.2021.154779_bb0095","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/liv.14722","article-title":"The association of low-grade albuminuria with incident nonalcoholic fatty liver disease and non-invasive markers of liver fibrosis by glycemic status","volume":"41","author":"Xin","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.metabol.2021.154779_bb0100","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.2337\/dc13-S067","article-title":"Diagnosis and classification of diabetes mellitus","volume":"36","author":"American Diabetes Association","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154779_bb0105","doi-asserted-by":"crossref","unstructured":"Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, Haflidadottir S, Day CP, George J. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145:782\u20139.e4. doi: https:\/\/doi.org\/10.1053\/j.gastro.2013.06.057.","DOI":"10.1053\/j.gastro.2013.06.057"},{"key":"10.1016\/j.metabol.2021.154779_bb0110","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.metabol.2015.09.017","article-title":"Non-alcoholic fatty liver disease and risk of cardiovascular disease","volume":"65","author":"Lonardo","year":"2016","journal-title":"Metabolism."},{"key":"10.1016\/j.metabol.2021.154779_bb0115","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut."},{"key":"10.1016\/j.metabol.2021.154779_bb0120","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3390\/nu5051544","article-title":"Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease","volume":"5","author":"Gaggini","year":"2013","journal-title":"Nutrients."},{"key":"10.1016\/j.metabol.2021.154779_bb0125","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41575-020-0316-6","article-title":"From NAFLD to MAFLD: when pathophysiology succeeds","volume":"17","author":"Tilg","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2021.154779_bb0130","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3390\/ijms17040460","article-title":"NAFLD and increased aortic stiffness: parallel or common physiopathological mechanisms?","volume":"17","author":"Villela-Nogueira","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2021.154779_bb0135","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.4254\/wjh.v7.i10.1325","article-title":"Oxidative stress: new insights on the association of non-alcoholic fatty liver disease and atherosclerosis","volume":"7","author":"Polimeni","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.metabol.2021.154779_bb0140","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.3748\/wjg.v26.i16.1861","article-title":"Macrophages in metabolic associated fatty liver disease","volume":"26","author":"Alharthi","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.metabol.2021.154779_bb0145","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hep.20781","article-title":"Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease","volume":"42","author":"Villanova","year":"2005","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2021.154779_bb0150","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.atherosclerosis.2014.09.011","article-title":"Inflammation and arterial stiffness in humans","volume":"237","author":"Jain","year":"2014","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.metabol.2021.154779_bb0155","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.3748\/wjg.v20.i37.13306","article-title":"Nonalcoholic fatty liver disease and vascular disease: state-of-the-art","volume":"20","author":"Fargion","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.metabol.2021.154779_bb0160","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41575-018-0010-0","article-title":"Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease","volume":"15","author":"Anstee","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049521000792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049521000792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T20:07:31Z","timestamp":1672344451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049521000792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":32,"alternative-id":["S0026049521000792"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2021.154779","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2021.154779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154779"}}